Hovid Bhd was recently in the corporate news for having a
VGO exercise launched by its major shareholder with the backing of a private
equity (PE) partner.
Its financials are slowly recovering, with its most recent quarterly
financials ended 31 March 2018 recording a turnaround back to profitability
since the license suspension of its drug manufacturing activity.
With the price reference of 38 sen per share as per the
entry price of the PE partner, another round of offer may be launched to take
the firm private for the final time, but all these are speculative currently as
no firm plans is on the cards to rectify the public shareholding spread issue.
The current spread between the 38 sen last anchor price and current ask price
of 33 sen is a sweet 15%, but by no means will narrow anytime soon.
Judging by the performance of last 3 financial quarters, a
return to annual profitability could potentially provide strong fundamental
support to its share price where P/E multiples are normalized.
Final thoughts:
Pros: Strong institutional shareholder price anchor at 38
sen per share.
Cons: Failure of operational turnaround and continued losses
due.
Note: This is not an investment advice. Buy and sell any
securities at your own risk.
